Lenita Hanson
Endocrinology, Diabetes & Metabolism · Port Charlotte, FLNPI 1225128572
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $53,975 of the $74,832 with a category attached, or 72.1%. Lilly USA, LLC accounts for 76.0% of it on its own, with 43 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 505 payments — averaging $148.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$57K
- Bayer$4K
- Insulet Corporation$4K
- Tandem Diabetes Care, Inc.$1K
- Boehringer Ingelheim International GmbH$1K
- Sanofi-aventis U.S. LLC$900
- plus $6K from 38 others
Across 798 payments — averaging $1539.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$359K
- Eli Lilly$256K
- Boehringer Ingelheim International GmbH$178K
- Bayer$144K
- Boehringer Ingelheim Pharma GmbH & Co.kg$140K
- Sanofi US Services Inc.$74K
- plus $78K from 7 others
What the payments were for
- Speaking & faculty fees$53,97572%
- Travel & lodging$9,51013%
- Food & beverage$11,26615%
- Education$820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPBOUND$44,778
- Omnipod$3,600
- Kerendia$3,008
- JARDIANCE$1,559
- t:slim X2 Insulin Pump with Control-IQ$1,325
- RYBELSUS$235
- FARXIGA$228
- ENROUTE Transcarotid Neuroprotection System$217
- NEXLIZET$125
- NEXLETOL$125
- DEXCOM G7 GSS (161)$125
- TEPEZZA$125
- TALTZ$125
- Synthroid$124
- MOUNJARO$123
- CRENESSITY$120
- FREESTYLE LIBRE 3$120
- INVOKANA$118
- ENROUTE Transcarotid Stent$109
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$109
How this compares
$74,832 in reported general payments places this provider in the 90th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 143 | $274,928 |
| MounjaroTirzepatide | 129 | $205,281 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 103 | $197,693 |
| JardianceEmpagliflozin | 77 | $104,056 |
| TrulicityDulaglutide | 61 | $88,853 |
| Tresiba Flextouch U-100Insulin Degludec | 87 | $73,201 |
| KerendiaFinerenone | 56 | $72,939 |
| Tresiba Flextouch U-200Insulin Degludec | 41 | $48,574 |
| FarxigaDapagliflozin Propanediol | 36 | $42,058 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 31 | $40,406 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 56 | $38,448 |
| RybelsusSemaglutide | 11 | $25,820 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 28 | $19,069 |
| FiaspInsulin Aspart (Niacinamide) | 13 | $18,324 |
| VascepaIcosapent Ethyl | 18 | $16,188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $746 | $334,315209 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $56,878 | $312,276271 claims |
| Boehringer IngelheimJardiance | $736 | $104,05677 claims |
| BayerKerendia | $4,242 | $72,93956 claims |
| AstraZenecaFarxiga | $562 | $42,05836 claims |
| MerckJanumet | $126 | $11,56811 claims |
| AbbVieSynthroid | $181 | $2,48335 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $18 | $1,391130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Port Charlotte
- Arelis MaderaPort Charlotte$1.7M
- Jay SkylerMiami$2.2M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Richard PratleyOrlando$735K
- Lee MetchickDeland$728K
- Misha DenhamCoral Gables$673K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.